Research Updates

Back to feed
PubMed

High importance

Sep 22, 2026

Permanent neurological morbidity after microsurgical resection of hereditary hemorrhagic telangiectasia-associated brain arteriovenous malformations: a systematic review and illustrative case.

View original source

Why it matters

Understanding the morbidity associated with surgical resection of HHT-related AVMs is crucial for improving patient management strategies, providing insights for risk assessment, and aiding shared decision-making between clinicians and patients.

Objective

To evaluate the difference in permanent neurological morbidity between surgical resection of hereditary hemorrhagic telangiectasia (HHT)-associated brain arteriovenous malformations (AVMs) and sporadic AVMs.

Results

The pooled incidence of new permanent neurological deficits among 91 patients with HHT-associated AVMs was found to be 9.9%. There was no significant difference when compared to sporadic AVM groups. However, one study accounted for 78% of the permanent deficits; excluding it reduced the morbidity rate to 2.9%. No postoperative mortality was reported.

Methods

A systematic review and meta-analysis of literature from PubMed, Embase, and Cochrane databases were conducted following PRISMA guidelines. The analysis compared rates of permanent neurological deficits in surgically treated HHT-associated AVMs with unselected sporadic AVM cases using Fisher's exact test.

Limitations

The analysis is limited by the small sample size and the potential heterogeneity among included studies. The findings are hypothesis-generating and not definitive, calling for further research.

For your doctor:

PMID: 42830897

DOI: 10.1016/j.bas.2026.107455

Abstract

INTRODUCTION: The optimal management of brain arteriovenous malformations (AVMs) in patients with hereditary hemorrhagic telangiectasia (HHT) remains controversial. Some authors recommend conservative management based on the presumed lower rupture risk compared to sporadic AVMs, others advocate surgical treatment. No systematic review has focused on permanent neurological morbidity following resection of HHT-associated AVMs, leaving a significant gap in the literature. RESEARCH QUESTION: Do the unique genetic features and angio-architecture of HHT-associated AVMs result in a different profile of postoperative neurological morbidity compared to sporadic AVMs? MATERIALS AND METHODS: A systematic search of PubMed, Embase, and Cochrane databases (1947-April 2026) was conducted per PRISMA 2020 guidelines; 18 publications reporting surgically treated HHT-associated brain AVMs were identified, 12 were included in the comparative analysis. Study quality was assessed using the Joanna Briggs Institute Critical Appraisal Checklist. Permanent morbidity rates were compared with unselected sporadic AVM series using Fisher's exact test with sensitivity analyses. RESULTS: Among 91 patients, pooled incidence of new permanent neurological deficits was 9.9% (95% CI: 4.6-18.0%). No significant difference was found compared to unselected sporadic AVM cohorts. One study contributed 78% of permanent deficit events; its exclusion reduced the rate to 2.9%. No postoperative mortality was reported. DISCUSSION AND CONCLUSION: No significant difference in permanent neurological morbidity was demonstrated between HHT-associated and sporadic AVM resections. However, the small sample size precludes definitive conclusions. These hypothesis-generating findings may aid in individualized risk assessment and shared decision-making. An illustrative case is presented to demonstrate the clinical context motivating this review.